And I've heard the same line of reasoning since .068 and there wasn't even a quarter of what has transpired since then - many of which I have already explicated- if I waited for all the "promises" to be fulfilled - I'd be one of those new investors buying ELTP at $1 or even $2.
1) The PPS has climbed from .068 to .238.
2) Hired an executive VP of Operations and a VP of Quality Operations and Regulatory Affiars. The first used to work at Actavis and the second at Alpharma.
3) Launched Generic Naltrexone and Isradipine.
4) Successful BE results of Eli 200 and 201 AND positive HAL data for Eli 200.
5) Garners 2 more ADT patents in Canada.
6) Garners $40 million in Funding for ART trials from LPC.
7) Adds 3 top executive positions including the previous IP lawyer from Alpharma and Sanofi Aventis.
8) Receives FDA guidance for Elite's Phase III efficacy trail for Eli 200 and has currently completed its Phase 3 withdrawal study.
9) Been approved for their Micro Tablet Patent which Elie will combine with its patented abuse resistat technology.
circle.... I could see your reasoning if this was 2011 again. Elite has come a long way since 2011. A very long way. They ARE on the cusp. Nothing in life is promised. What the company would like to see happen is sometimes not the way it turns out.. but this is about as close as one can get to things coming to fruition.
News 
Market Data 
Discover 
